Optiscan Advances GI Imaging with New Study in Germany

Tackling a Major Health Challenge
Gastrointestinal (GI) diseases, including colorectal cancer, are a significant global health issue. In 2020 alone, there were an estimated 1.9 million new cases of colorectal cancer and more than 930,000 related deaths worldwide. Early detection and precise intervention are crucial, but traditional diagnostic methods often lack the real-time precision required for effective treatment decisions.

Optiscan Imaging Limited (ASX:OIL) is working to change that. The company has announced the completion of its first prototype designed to capture images from the GI tract and the commencement of a pre-clinical GI study in partnership with the University Medical Center Mainz, Germany.

Advancing Real-Time Imaging
The study will evaluate the real-time imaging capabilities of Optiscan’s Gen2 technology on GI tract tissue. The collected data will not only assist in diagnosing and treating GI diseases but also support the development of artificial intelligence (AI) algorithms for improved image analysis.

Optiscan CEO & Managing Director, Dr. Camile Farah, emphasised the significance of this milestone.
“We are thrilled to be undertaking this study with the prestigious University Medical Center Mainz under the leadership of world-renowned gastroenterologist Professor Ralph Kiesslich. This represents a major step forward in helping to better understand and manage one of the world’s biggest health challenges.”

Building a Next-Generation Device
Optiscan’s Gen2 technology is part of a broader development strategy aimed at producing its next-generation flexible endomicroscope, the Gen3 device. Data gathered from this pre-clinical study will inform future clinical trials and assist in optimising the Gen3 platform.

“Our partnership with Professor Kiesslich and his team represents a pivotal step forward in extending the capabilities of Optiscan’s real-time, high-resolution imaging technology,” said Dr. Farah. “We are planning to re-enter the GI endoscopy market with our own private-label device.”

Professor Kiesslich has played a key role in the design and deployment of Optiscan’s Gen1 flexible endomicroscope in partnership with Pentax in the early 2000s. His expertise will be instrumental in advancing the next-generation device.

Enhancing Diagnosis with AI
The study will also contribute to AI development, with imaging datasets of various disease processes feeding into machine-learning models. Optiscan is collaborating with Monash University’s Cooperative Research Centre Project (CRC-P) to refine these AI algorithms, which could lead to even faster and more accurate GI disease detection.

What’s Next?
With the pre-clinical phase now active, Optiscan is preparing for the clinical phase of its research. Ethical clearance is being pursued, and updates will be provided as milestones are reached.

By combining cutting-edge real-time imaging with AI-driven diagnostics, Optiscan aims to improve the detection and treatment of GI diseases, reducing the reliance on traditional invasive methods and ultimately improving patient outcomes.

• About
• Latest Posts

Tim Grey

Latest posts by Tim Grey (see all)

• Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum - December 3, 2025
• SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition - November 18, 2025
• Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards - November 7, 2025